Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patients - A Confirmatory Phase III MNCCTN Trial

NCT05403580 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05403580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05403580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patients - A Confirmatory Phase III MNCCTN Trial
Lead sponsor
Mayo Clinic
Phase
Phase 3
Overall status
Withdrawn
Start date
June 3, 2022
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm